1 March 2017 in Protein Science
Synthetic binding proteins are constructed using nonantibody molecular scaffolds. Over the last two decades, in‐depth structural and functional analyses of synthetic binding proteins have improved combinatorial library designs and selection strategies, which have resulted in potent platforms that consistently generate binding proteins to diverse targets with affinity and specificity that rival those of antibodies. Favorable attributes of synthetic binding proteins, such as small size, freedom from disulfide bond formation and ease of making fusion proteins, have enabled their unique applications in protein science, cell biology and beyond. Here, we review recent studies that illustrate how synthetic binding proteins are powerful probes that can directly link structure and function, often leading to new mechanistic insights. We propose that synthetic proteins will become powerful standard tools in diverse areas of protein science, biotechnology and medicine.
1 September 2016 in Neuron
5 September 2017 in Proceedings of the National Academy of Sciences
Adhesion G protein-coupled receptors (aGPCRs) play critical roles in diverse biological processes, including neurodevelopment and cancer progression. aGPCRs are characterized by large and diverse extracellular regions (ECRs) that are autoproteolytically cleaved from their membrane-embedded signaling domains. Although ECRs regulate receptor function, it is not clear whether ECRs play a direct regulatory role in G-protein signaling or simply serve as a protective cap for the activating “Stachel” sequence. Here, we present a mechanistic analysis of ECR-mediated regulation of GPR56/ADGRG1, an aGPCR with two domains [pentraxin and laminin/neurexin/sex hormonebinding globulin-like (PLL) and G protein-coupled receptor autoproteolysis-inducing (GAIN)] in its ECR. We generated a panel of high-affinity monobodies directed to each of these domains, from which we identified activators and inhibitors of GPR56-mediated signaling. Surprisingly, these synthetic ligands modulated signaling of a GPR56 mutant defective in autoproteolysis and hence, in Stachel peptide exposure. These results provide compelling support for a ligand-induced and ECR-mediated mechanism that regulates aGPCR signaling in a transient and reversible manner, which occurs in addition to the Stachel-mediated activation. Significance G protein-coupled receptors enable cells to sense extracellular signals and translate them into physiological responses. In addition to a transmembrane domain that transduces signals into the cytoplasm, adhesion G protein-coupled receptors (aGPCRs) have large extracellular regions (ECRs) that interact with proteins in the extracellular space. The goal of this study is to elucidate how ECRs control aGPCR activation. We engineered synthetic binding proteins, termed monobodies, that bind specific domains in the ECR and showed that monobodies can activate or inhibit G-protein signaling. Our data conclusively establish the feasibility of controlling aGPCR signaling using ECR-targeted drug-like molecules and support a model in which ligand binding to the ECR can affect the transmembrane domain and modulate signal transduction.